Climate change is the single biggest threat to the global environment and socio-economic development – demanding an urgent transformation of the United Nations’ Sustainable Development Goals. 

Despite a heavy infusion of public and private support during the COVID-19 pandemic, Medicaid and Medicare beneficiaries in Oregon reported that housing and food insecurity shot up during the onset of the pandemic in March of 2020 — and their basic needs remained in doubt through at least the end of the following year. The survey data were reported in a study led by Oregon Health & Science University and published today in the Annals of Family Medicine.

About The Study: This study estimates that approximately one-third of U.S. adults without diabetes who were eligible for weight loss treatment with glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GLP-1/GIP) were excluded from clinical trials supporting these medications’ safety and effectiveness. Until there is evidence from high-quality postmarketing studies, the FDA should consider updating labeling to advise caution on generalizing the safety and effectiveness of GLP-1 and GLP-1/GIP to populations excluded from pivotal trials.